Modification of the Actions of Some Neuroactive Drugs by Growth Hormone
- 1 February 1976
- journal article
- research article
- Published by American Medical Association (AMA) in Archives of Neurology
- Vol. 33 (2), 131-134
- https://doi.org/10.1001/archneur.1976.00500020059009
Abstract
• The flat serum growth hormone (GH) patterns of untreated parkinsonian patients develop diurnal rises during treatment with levodopa. This chronic exposure to excesses of GH might lead to the eventual emergence of the "on-off" phenomenon, which would indicate a need for animal experiments. Pretreatment of mice with GH increased (1) cerebral dopa and dopamine concentrations in levodopa-treated mice, (2) cerebral accumulation of injected tritiated apomorphine and tritiated thymidine, and (3) behavioral responses to levodopa, L-m-tyrosine, apomorphine hydrochloride, and oxotremorine.Keywords
This publication has 8 references indexed in Scilit:
- Changing the Actions of Neuroactive Drugs by Changing Brain Protein SynthesisProceedings of the National Academy of Sciences, 1974
- Monoamine Oxidase and Cerebral Uptake of Dopaminergic DrugsProceedings of the National Academy of Sciences, 1974
- Metabolic Responses to Acute and Chronicl-Dopa Administration in Patients with ParkinsonismNew England Journal of Medicine, 1972
- Dopamine-sensitive adenylate cyclase in caudate nucleus of rat brain, and its similarity to the “dopamine receptor”Proceedings of the National Academy of Sciences, 1972
- Action of various centrally acting agents in mice with unilateral caudate brain lesionsLife Sciences, 1971
- A Protein Binding Assay for Adenosine 3′:5′-Cyclic MonophosphateProceedings of the National Academy of Sciences, 1970
- Modification of Parkinsonism — Chronic Treatment with L-DopaNew England Journal of Medicine, 1969
- A sensitive and specific assay for the estimation of monoamine oxidaseBiochemical Pharmacology, 1963